New-Onset Atrial Flutter in Pneumonia: A Systemic Inflammatory Response With Cardiac Implications

肺炎新发心房扑动:一种具有心脏影响的全身炎症反应

阅读:1

Abstract

Atrial arrhythmias, particularly atrial flutter, are increasingly recognized as complications of systemic infections, including community-acquired pneumonia (CAP). This report describes the case of a 60-year-old male with CAP complicated by new-onset atrial flutter, highlighting the role of systemic inflammation and electrolyte imbalances in arrhythmogenesis. The systemic inflammatory response associated with pneumonia leads to cytokine-mediated atrial remodeling, autonomic dysfunction, and direct myocardial stress, all of which can contribute to atrial flutter. Furthermore, electrolyte disturbances such as hypokalemia and hyponatremia, both present in this patient, exacerbate cardiac excitability, prolong repolarization, and promote reentry circuits, increasing susceptibility to atrial flutter compared to other arrhythmias. Despite the severity of the arrhythmia, cardioversion was not considered in this case, as the patient remained hemodynamically stable with effective rate control achieved through IV amiodarone. Instead, management focused on targeted interventions, including electrolyte correction, infection control, and anticoagulation therapy, to mitigate thromboembolic risk. Given the well-documented link between systemic inflammation, electrolyte imbalances, and arrhythmias, early monitoring of electrolytes, inflammatory markers, and ECG in pneumonia patients may allow for timely interventions and improved clinical outcomes. Future research should focus on prospective trials evaluating standardized arrhythmia screening and electrolyte correction protocols in pneumonia patients at high risk for cardiovascular complications. Retrospective cohort studies assessing the impact of inflammation-targeted therapies on arrhythmia incidence may also help refine clinical guidelines. Recognizing pneumonia as a multi-system disease rather than an isolated respiratory infection may lead to improved risk stratification and therapeutic strategies, ultimately improving patient outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。